Research Analysts Set Expectations for FMS Q4 Earnings

Fresenius Medical Care AG (NYSE:FMS - Free Report) - Analysts at Zacks Research increased their Q4 2026 earnings per share estimates for shares of Fresenius Medical Care in a report released on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will earn $0.62 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for Fresenius Medical Care's current full-year earnings is $1.55 per share.

Several other equities research analysts have also weighed in on the company. StockNews.com started coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They issued a "strong-buy" rating on the stock. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price objective on the stock. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, Truist Financial raised their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $24.30.

Fresenius Medical Care Stock Performance

Shares of NYSE FMS traded down $0.49 during mid-day trading on Thursday, hitting $22.15. The company had a trading volume of 233,877 shares, compared to its average volume of 353,043. Fresenius Medical Care has a 12 month low of $17.93 and a 12 month high of $24.31. The stock has a market cap of $13.00 billion, a price-to-earnings ratio of 18.31, a PEG ratio of 0.96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm's 50 day simple moving average is $22.21 and its two-hundred day simple moving average is $20.64.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Wulff Hansen & CO. boosted its holdings in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock valued at $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Moran Wealth Management LLC lifted its position in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock worth $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP boosted its stake in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock valued at $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Fresenius Medical Care by 60.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after purchasing an additional 23,692 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fresenius Medical Care in the 3rd quarter worth $420,000. Institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.